NCT07674680

Brief Summary

To determine if vascular beta3 adrenergic receptors are present and functional in aging women and can be targeted to attenuate sympathetic vasoconstriction and enhance vascular function in aging women.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P75+ for early_phase_1

Timeline
34mo left

Started Jul 2026

Typical duration for early_phase_1

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress3%
Jul 2026May 2029

First Submitted

Initial submission to the registry

June 17, 2026

Completed
12 days until next milestone

First Posted

Study publicly available on registry

June 29, 2026

Completed
2 days until next milestone

Study Start

First participant enrolled

July 1, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2028

Expected
1 year until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2029

Last Updated

July 28, 2026

Status Verified

June 1, 2026

Enrollment Period

1.8 years

First QC Date

June 17, 2026

Last Update Submit

July 24, 2026

Conditions

WomenAgingMenopause

Outcome Measures

Primary Outcomes (1)

  • Blood flow

    Blood flow measured with Doppler ultrasound.

    Change from baseline to minute 2.

Study Arms (2)

Cold pressor test

EXPERIMENTAL

Participants will be exposed to the cold pressor test (ice water on the foot).

Drug: PlaceboDrug: Gemtesa

Flow Mediated Dilation

EXPERIMENTAL

Participants will be exposed to the high-resolution ultrasound following inflation of a cuff around the forearm.

Drug: PlaceboDrug: Gemtesa

Interventions

PlaceboDRUG

Participants will receive a placebo in pill form.

Cold pressor testFlow Mediated Dilation
GemtesaDRUG

Participants will receive oral gemtesa (75 mg).

Cold pressor testFlow Mediated Dilation

Eligibility Criteria

Age18 Years - 70 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Healthy women,
  • Assigned female at birth,
  • years of age,
  • Body mass index \<18 or ≥30 kg/m2,

You may not qualify if:

  • Assigned male at birth,
  • Pregnancy,
  • Breastfeeding,
  • History of hormone replacement therapy, chemical menopause, or oophor-ectomy
  • Polycystic ovarian syndrome or Primary ovarian insufficiency,
  • Current smoking/Nicotine use,
  • Blood pressure ≥140/90 mmHg,
  • Increased risk of bleeding, pro-coagulant disorders, clotting disorders, anticoagulation therapy,
  • Nerve/neurologic disease,
  • Cardiovascular, hepatic, renal, respiratory disease,
  • Hypersensitivity to nitroglycerin,
  • Diabetes,
  • Communication barriers,

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Missouri

Columbia, Missouri, 65211, United States

Location

Central Study Contacts

Jacqueline Limberg Associate Professor

CONTACT

1-573-882-2544limberglab@missouri.edu

Study Design

Study Type
interventional
Phase
early phase 1
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

June 17, 2026

First Posted

June 29, 2026

Study Start

July 1, 2026

Primary Completion (Estimated)

May 1, 2028

Study Completion (Estimated)

May 1, 2029

Last Updated

July 28, 2026

Record last verified: 2026-06

Locations

US(1)